Patents by Inventor Ian Kirby

Ian Kirby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND IMMUNOCYTOKINES
    Publication number: 20170362321
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: April 6, 2017
    Publication date: December 21, 2017
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • ANTIBODIES, USES & METHODS
    Publication number: 20170327587
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 16, 2017
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20170327586
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 16, 2017
    Applicant: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • ANTI-LIGHT ANTIBODIES
    Publication number: 20170320956
    Abstract: The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.
    Type: Application
    Filed: June 16, 2017
    Publication date: November 9, 2017
    Applicant: KYMAB LIMITED
    Inventors: Jamie Iain CAMPBELL, Bettina FRANZ, Steve HOLMES, Ian KIRBY, Anais LEGENT
  • ANTI-LIGHT ANTIBODIES
    Publication number: 20170291951
    Abstract: The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.
    Type: Application
    Filed: January 13, 2015
    Publication date: October 12, 2017
    Applicant: KYMAB LIMITED
    Inventors: Jamie Iain CAMPBELL, Bettina FRANZ, Steve HOLMES, Ian KIRBY, Anais LEGENT
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20170260279
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: May 24, 2017
    Publication date: September 14, 2017
    Applicant: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
    Publication number: 20170152312
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: February 9, 2017
    Publication date: June 1, 2017
    Inventors: Gary Peter BEMBRIDGE, Chun-wa Chung, Susannah Karen FORD, Ian KIRBY, Ruth MCADAM, Maria FEENEY
  • ANIMAL MODELS AND THERAPEUTIC MOLECULES
    Publication number: 20170099816
    Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 13, 2017
    Inventors: Allan BRADLEY, E-Chiang LEE, Qi LIANG, Wei WANG, Anais LEGENT, Ian KIRBY
  • Antibodies and immunocytokines
    Patent number: 9617338
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: April 11, 2017
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • ANIMAL MODELS AND THERAPEUTIC MOLECULES
    Publication number: 20170094956
    Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Inventors: Allan BRADLEY, E-Chiang LEE, Qi LIANG, Wei WANG, Anais LEGENT, Ian KIRBY
  • Antigen binding proteins to Oncostatin M (OSM)
    Patent number: 9605063
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 28, 2017
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • ANIMAL MODELS AND THERAPEUTIC MOLECULES
    Publication number: 20170071174
    Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Inventors: Allan BRADLEY, E-Chiang LEE, Wei WANG, Qi LIANG, Anais LEGENT, Ian KIRBY
  • Anti-hOX40L antibodies, uses, and methods
    Patent number: 9587030
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: March 7, 2017
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
  • Antibodies, Uses & Methods
    Publication number: 20170044250
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: November 1, 2016
    Publication date: February 16, 2017
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Antibodies and immunocytokines
    Patent number: 9567399
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 14, 2017
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20170037137
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: October 25, 2016
    Publication date: February 9, 2017
    Applicant: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • Antibodies, Uses & Methods
    Publication number: 20170002083
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: September 8, 2016
    Publication date: January 5, 2017
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Antibodies, Uses & Methods
    Publication number: 20160368997
    Abstract: The present invention relates to anti-human OX4OL antibodies, new medical uses and methods.
    Type: Application
    Filed: March 3, 2015
    Publication date: December 22, 2016
    Applicant: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Synergistic combinations of OX40L antibodies for the treatment of GVHD
    Patent number: 9512229
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 6, 2016
    Assignee: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • ANIMAL MODELS AND THERAPEUTIC MOLECULES
    Publication number: 20160345551
    Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
    Type: Application
    Filed: July 20, 2016
    Publication date: December 1, 2016
    Inventors: Allan BRADLEY, E-Chiang LEE, Qi LIANG, Wei WANG, Anais LEGENT, Ian KIRBY